Identification of gene networks and pathways associated with Guillain-Barré syndrome

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Chang, Kuo Hsuan ^a   Chuang, Tzi Jung ^a   Lyu, Rong Kuo ^a   Ro, Long Sun ^a   Wu, Yih Ru ^a   Chang, Hong Shiu ^a   Huang, Chin Chang ^a   Kuo, Hung Chou ^a   Hsu, Wen Chuin ^a   Chu, Chun Che ^a   Chen, Chiung Mei ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEFENSIN; GELATINASE B; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; GONADORELIN; HEMOGLOBIN; HIGH MOBILITY GROUP B2 PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PROSTAGLANDIN SYNTHASE; PROTEIN MD 2; SELENIUM BINDING PROTEIN; MATRIX METALLOPROTEINASE; TRANSCRIPTOME;

ARTICLE; CELL DEATH; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL MOTION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; LEUKOCYTE; MICROARRAY ANALYSIS; QUANTITATIVE ANALYSIS; STANDARDIZATION; UPREGULATION; CASE CONTROL STUDY; DOWN REGULATION; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANNEXIN A3; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GENE REGULATORY NETWORKS; GUILLAIN-BARRE SYNDROME; HUMANS; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTOME; UP-REGULATION;

EID: 84855569573     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029506     Document Type: Article

References (77)

1. Hughes RAC, Cornblath DR, (2005) Guillain-Barré syndrome. Lancet 366: 1653-1666.
2. Sejvar JJ, Baughman AL, Wise M, Morgan OW, (2011) Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36: 123-133.
3. Cosi V, Versino M, (2006) Guillain-Barré syndrome. Neurol Sci 27 (Suppl 1): S47-51.
4. Hughes RA, Rees JH, (1997) Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 176 (Suppl 2): S92-98.
5. Kang JH, Sheu JJ, Lin HC, (2010) Increased risk of Guillain-Barré syndrome following recent herpes zoster: A population-based study across Taiwan. Clin Infect Dis 51: 525-530.
6. Rees JH, Soudain SE, Gregson NA, Hughes RA, (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333: 1374-1379.
7. Wim Ang C, Jacobs BC, Laman JD, (2004) The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 25: 61-66.
8. Susuki K, Odaka M, Mori M, Hirata K, Yuki N, (2004) Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry. Neurology 62: 949-956.
9. Kwa MSG, van Schaik IN, Brand A, Baas F, Vermeulen M, (2001) Investigation of serum response to PMP22, connexin 32 and P0 in inflammatory neuropathies. J Neuroimmunol 116: 220-225.
10. Kusunoki S, Kaida K, (2011) Antibodies against ganglioside complexes in Guillain-Barré syndromé and related disorders. J Neurochem 116: 828-832.
11. Kuijf ML, Samsom JN, van Rijs W, Bax M, Huizinga R, et al. (2010) TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol 185: 748-755.
12. Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, et al. (1998) Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol 81: 116-126.
13. Gabriel CM, Gregson NA, Hughes RAC, (2000) Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 104: 139-146.
14. Willison HJ, Yuki N, (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625.
15. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, et al. (1996) Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39: 625-635.
16. Hafer-Macko C, Hsieh ST, Ho TW, Sheikh K, Cornblath DR, et al. (1996) Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 40: 635-644.
17. Griffin J, Li C, Macko C, Ho T, Hsieh S, et al. (1996) Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 25: 33-51.
18. Creange A, Sharshar T, Planchenault T, Christov C, Poron F, et al. (1999) Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome. Neurology 53: 1683-1691.
19. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, et al. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131-156.
20. Asbury AK, Arnason BG, Adams RD, (1969) The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 48: 173-215.
21. Prineas JW, (1981) Pathology of the Guillain-Barré syndrome. Ann Neurol 9: 6-19.
22. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, et al. (1996) Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 39: 17-28.
23. Marchiori PE, Dos Reis M, Quevedo ME, Callegaro D, Hirata MT, et al. (1990) Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. Arq Neuropsiquiatr 48: 465-468.
24. Petzold A, Hinds N, Murray NF, Hirsch NP, Grant D, et al. (2006) CSF neurofilament levels: A potential prognostic marker in Guillain-Barré syndrome. Neurology 67: 1071-1073.
25. Matà S, Galli E, Amantini A, Pinto F, Sorbi S, et al. (2006) Anti-ganglioside antibodies and elevated CSF IgG levels in Guillain-Barré syndrome. Eur J Neurol 13: 153-160.
26. Mokuno K, Kiyosawa K, Sugimura K, Yasuda T, Riku S, et al. (1994) Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barré syndrome. Acta Neurol Scand 89: 27-30.
27. Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, et al. (2003) CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology 61: 823-825.
28. Nagai A, Murakawa Y, Terashima M, Shimode K, Umegae N, et al. (2000) Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 55: 1828-1832.
29. Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, et al. (2009) Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 405: 143-147.
30. Jin T, Hu LS, Chang M, Wu J, Winblad B, et al. (2007) Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 14: 563-568.
31. Chang KH, Lyu RK, Tseng MY, Ro LS, Wu YR, et al. (2007) Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. Proteomics Clin Appl 1: 467-475.
32. D'Aguanno S, Franciotta D, Lupisella S, Barassi A, Pieragostino D, et al. (2010) Protein profiling of Guillain-Barré syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. Neurosci Lett 485: 49-54.
33. Weller M, Stevens A, Sommer N, Melms A, Dichgans J, et al. (1991) Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. J Neurol Sci 104: 215-221.
34. Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Naldi P, et al. (2010) The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 51: 138-143.
35. Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV, (1987) Guillain-Barré syndrome: activated complement components C3a and C5a in CSF. Neurology 37: 1006-1009.
36. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM, (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2: 750-753.
37. Wagner EF, Eferl R, (2005) Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208: 126-140.
38. Wang W, Lin C, Lu D, Ning Z, Cox T, et al. (2008) Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci U S A 105: 9290-9295.
39. Hu W, Mathey E, Hartung HP, Kieseier BC, (2003) Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 61: 1774-1779.
40. Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, et al. (2002) New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25: 280-282.
41. Miyamoto K, Oka N, Kawasaki T, Satoi H, Akiguchi I, et al. (1998) The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis. Neuro Report 9: 2331-2334.
42. Miyamoto K, Oka N, Kawasaki T, Satoi H, Matsuo A, et al. (1999) The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis. Muscle Nerve 22: 1704-1709.
43. Kumar K, Singal A, Rizvi MM, Chauhan VS, (2008) High mobility group box (HMGB) proteins of Plasmodium falciparum: DNA binding proteins with pro-inflammatory activity. Parasitol Int 57: 150-157.
44. Randell SH, Shimizu T, Bakewell W, Ramaekers FC, Nettesheim P, (1993) Phenotypic marker expression during fetal and neonatal differentiation of rat tracheal epithelial cells. Am J Respir Cell Mol Biol 8: 546-555.
45. Proost P, Van Damme J, Opdenakker G, (1993) Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192: 1175-1181.
46. Sharshar T, Durand MC, Lefaucheur JP, Lofaso F, Raphael JC, et al. (2002) MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barré syndrome. Neurology 59: 1649-1651.
47. Nyati KK, Prasad KN, Verma A, Paliwal VK, (2010) Correlation of matrix metalloproteinases-2 and-9 with proinflammatory cytokines in Guillain-Barré syndrome. J Neurosci Res 88: 3540-3546.
48. Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, et al. (1998) Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 43: 427-434.
49. Hughes P, Wells G, Clements J, Gearing A, Redford E, et al. (1998) Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 121: 481-494.
50. Redford E, Smith K, Gregson N, Davies M, Hughes P, et al. (1997) A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 120: 1895-1905.
51. Zhao XL, Li GZ, Sun B, Zhang ZL, Yin YH, et al. (2010) MMP-mediated cleavage of beta-dystroglycan in myelin sheath is involved in autoimmune neuritis. Biochem Biophys Res Commun 392: 551-556.
52. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN, (2001) MD-2 Binds to Bacterial Lipopolysaccharide. J Biol Chem 276: 38044-38051.
53. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189: 1777-1782.
54. Miyake K, (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Sem Immunol 19: 3-10.
55. Wang BY, Xu GL, Zhou CH, Tian L, Xue JL, et al. (2010) ΦC31 integrase interacts with TTRAP and inhibits NFκB activation. Mol Biol Rep 37: 2809-2816.
56. Pype S, Declercq W, Ibrahimi A, Michiels C, Van Rietschoten JGI, et al. (2000) TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-κB activation. J Biol Chem 275: 18586-18593.
57. Gerke V, Moss SE, (2002) Annexins: From structure to function. Physiol Rev 82: 331-371.
58. Kessler C, Junker H, Balseanu TA, Oprea B, Pirici D, et al. (2008) Annexin A3 expression after stroke in the aged rat brain. Rom J Morphol Embryol 49: 27-35.
59. Park JE, Lee DH, Lee JA, Park SG, Kim NS, et al. (2005) Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 337: 1283-1287.
60. Mayr B, Montminy M, (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599-609.
61. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102: 4459-4464.
62. Gómez-Martín D, Díaz-Zamudio M, Crispín JC, Alcocer-Varela J, (2009) Interleukin 2 and systemic lupus erythematosus: Beyond the transcriptional regulatory net abnormalities. Autoimmun Rev 9: 34-39.
63. Sitaraman SV, Merlin D, Wang L, Wong M, Gewirtz AT, et al. (2001) Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest 107: 861-869.
64. Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, et al. (2002) Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105: 2760-2765.
65. Jander S, Heidenreich F, Stoll G, (1993) Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 43: 1809-1813.
66. Del Giudice E, Savoldi G, Notarangelo L, Di Benedetto L, Manganelli F, et al. (2003) Acute inflammatory demyelinating polyradiculoneuropathy associated with perforin-deficient familial haemophagocytic lymphohistiocytosis. Acta Pædiatrica 92: 398-401.
67. Harness J, McCombe PA, (2008) Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci 15: 1031-1035.
68. Weishaupt A, Brück W, Hartung T, Toyka KV, Gold R, (2001) Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α. Neurosci Lett 306: 77-80.
69. Øren A, White LR, Aasly J, (2001) Apoptosis in neurones exposed to cerebrospinal fluid from patients with multiple sclerosis or acute polyradiculoneuropathy. J Neurol Sci 186: 31-36.
70. Tomaszewska-Zaremba D, Herman A, (2009) The role of immunological system in the regulation of gonadoliberin and gonadotropin secretion. Reprod Biol 9: 11-23.
71. Battaglia DF, Brown ME, Krasa HB, Thrun LA, Viguie C, et al. (1998) Systemic challenge with endotoxin stimulates corticotropin-releasing hormone and arginine vasopressin secretion into hypophyseal portal blood: Coincidence with gonadotropin-releasing hormone suppression. Endocrinology 139: 4175-4181.
72. Dong C, Davis RJ, Flavell RA, (2002) MAP kinases in the immune response. Ann Rev Immunol 20: 55-72.
73. Sheu JY, Kulhanek DJ, Eckenstein FP, (2000) Differential patterns of ERK and STAT3 phosphorylation after sciatic nerve transection in the rat. Exp Neurol 166: 392-402.
74. Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, et al. (2004) Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci 24: 6724-6732.
75. Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, et al. (2004) The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 23: 3061-3071.
76. Agthong S, Kaewsema A, Tanomsridejchai N, Chentanez V, (2006) Activation of MAPK ERK in peripheral nerve after injury. BMC Neurosci 7: 45.
77. Asbury AK, Cornblath DR, (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 (Suppl): S21-24.